Biocryst Pharmaceuticals (BCRX) stock’s relative strength (RS) rating was raised from 88 to 92 on Wednesday.
x
When looking for the best stocks to buy and watch, one factor to take a closer look at is relative price power. This unique rating measures market leadership by showing how the stock price compared to other stocks in our database over the past 52 weeks.
Decades of market research shows that the best stocks have an RS rating of at least 80 as they begin their biggest price moves.
Looking for winning stocks? Try This Simple Routine
Is Biocrystal Pharmaceutical Stock a Buy?
In February, Biocrystal Pharmaceuticals’ stock had a failed breakout from a cup-shaped basis. While the biotech stock is nowhere near an ideal entry, see if it is able to form and break a proper chart pattern. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.
Earnings growth fell from 0% to -21% in the most recent report. But the revenue profit increased from 572% to 1,073 per cent.
Biocryst Pharmaceuticals stock earns the No. 48 rank among its peers in the medical-biomed/biotech industry group. Pachira Pharmaceuticals (PCRX), Amphastar Pharmaceuticals (AMPH) and Vertex Pharmaceuticals (VRTX) is included in the top 5 highly rated stocks of the group. For more industry group news, see “Biotech and pharmaceutical industry and stock news.”
IBD Newsletters
Receive exclusive IBD analysis and actionable news daily.
Sign up now!
IBD Newsletters
Receive exclusive IBD analysis and actionable news daily.
Please enter a valid e-mail address
Please choose a newsletter
Go
Get these newsletters delivered to your inbox and find out more about our products and services. Privacy Policy, Terms of Use
x
Thank you!
You will now receive the IBD newsletter
all done!
something went wrong!
please contact customer service
To close
You might also like:
MarketSmith’s Tools Can Help the Individual Investor
IBD Live: A New Tool for Daily Stock Market Analysis
Profit from short term trends with Swing Trader
How to Research Growth Stocks: Why This IBD Tool Makes Finding Top Stocks Easier?
